What is Angelman syndrome?

Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people – about 500,000 individuals worldwide. Children and adults with AS typically have balance issues, motor impairment and debilitating seizures. Some individuals never walk. Most do not speak. Disrupted sleep cycles also can be a serious challenge to the individual and caregivers(s). Individuals with AS require continuous care and are unable to live independently. They have a normal life expectancy. This is life today for people living with Angelman syndrome, but hope is here. Scientists believe that AS has the greatest potential for being cured when compared to other neurogenetic disorders, and FAST (Foundation for Angelman Syndrome Therapeutics) has a plan well underway to achieve just that.

 

Research and impact

Our sole mission is to alleviate all the symptoms of Angelman syndrome. That’s why we joined forces with FAST United States who brought together a multidisciplinary team of more than two-dozen scientists from top research universities and pharmaceutical companies. These men and women are the nation’s foremost authorities on Angelman syndrome (AS), and they have joined forces on a focused path to a cure. We work closely with the team in the US, and other branches of FAST around the4 world to enure our research is targetted towards our mutal goal; a cure.

 

About FAST Australia

Our Board of Directors utilise their expertise in various fields to advance our mission, assess our strategies and create opportunities to aggressively pursue our goals. We have oversight from nationally and internationally recognised clinicians and scientists considered experts in their respective fields that make up our Scientific Advisory Board.
 
As an Australian business, and a Health Promotion Charity with DGR status we realise that transparency is vitally important to our members. Our record with the Australian Charities and Not-for-Profits Commission (ACNC) including governance and financials, can be found here.

More about Angelman Syndrome

Learn further information on the cause, testing and the prognosis of Angelan syndrome...>

Our research

Read about projects funded and co funded by FAST Australia.>

Our team

Meet our board of directors and scientific advisory team.>


Copyright © Foundation for Angelman Syndrome Therapeutics • Privacy Policy | Terms of Use
F.A.S.T. Australia • PO Box 248 • Salisbury • Queensland • 4107 • Phone 1300 078 108 • FAX 07 4032 5255